Calon Cardio-Technology
Financials
Estimates*
EUR | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
---|---|---|---|---|---|---|---|
Revenues | - | - | - | <1m | <1m | - | <1m |
% growth | - | - | - | - | (89 %) | - | - |
EBITDA | (<1m) | (2.3m) | (1.9m) | (2.2m) | (3.2m) | (1.9m) | (1.3m) |
% EBITDA margin | - | - | - | (479 %) | (6434 %) | - | (13220 %) |
Profit | (<1m) | (2.2m) | (1.8m) | (1.8m) | (3.1m) | (1.8m) | (<1m) |
% profit margin | - | - | - | (392 %) | (6221 %) | - | (6427 %) |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
£1.5m | Series B | ||
£1.2m | Seed | ||
£490k | Grant | ||
Total Funding | $4.2m |
Recent News about Calon Cardio-Technology
EditCalon Cardio Technology specializes in developing advanced heart pumps, specifically Left Ventricular Assist Devices (LVADs), aimed at treating chronic heart failure. The company operates in the medical device market, focusing on patients suffering from severe heart conditions who require mechanical circulatory support. Calon Cardio's primary clients are healthcare providers and hospitals that treat patients with chronic heart failure, a condition affecting around 26 million people in the developed world.
The business model revolves around the research, development, and eventual commercialization of their LVAD technology. Calon Cardio is currently seeking investment to proceed to first-in-human studies, which is a critical step towards bringing their product to market. Revenue will be generated through the sale of these devices to medical institutions and possibly through partnerships or licensing agreements with larger medical device companies.
Calon Cardio's innovative approach addresses the limitations of early-generation pumps, which were large, heavy, and required highly invasive surgery. Their technology aims to offer a more reliable and durable solution with fewer adverse effects like haemolysis and thrombosis.
Keywords: heart pump, LVAD, chronic heart failure, mechanical circulatory support, medical device, heart transplant alternative, healthcare providers, investment, human studies, advanced treatment.